Gestalt Diagnostics’ PathFlow Selected by BioReference Laboratories for Pathology Laboratory Business
Gestalt Diagnostics today announced, that BioReference Laboratories Inc., an OPKO Health company, has selected their digital pathology solution.
PathFlow®, to support its pathology
business. PathFlow is an enterprise software platform specifically designed to bring the benefits of digital
workflow to pathologists and pathology laboratories.
Under the agreement, Gestalt is partnering with Leica Biosciences, which provides whole slide imaging
scanners, and MindPeak, which provides integrated AI algorithms within Gestalt's PathFlow. The ability to
provide the full cycle of digital pathology to BioReference is an example of the acceleration in the advances of
technologies and interoperability that are available for integration directly within the pathologist's workflow.
"Speaking on behalf of our team, we are honored to be the chosen vendor to support BioReference Lab's
adoption of digital pathology. We look forward to enabling their pathologists to use innovative workflow and AI
tools to support the diagnosis of disease including breast cancer.”, says Dan Roark, Chief Executive Officer,
Gestalt Diagnostics.
“Our ability to partner, and interface, with multiple vendors provides a highly interoperable platform with a
simple delivery and user experience, enabling their pathologists to achieve their goals of streamlined,
interoperable digital pathology with computer aided diagnostic algorithms. BioReference will be using ER, PR,
Ki-67, HER2, and P53 AI algorithms for breast diagnostics integrated directly within our digital platform,
PathFlow", says Lisa-Jean Clifford, COO & Chief Strategy Officer, Gestalt Diagnostics.
About Gestalt Diagnostics
Gestalt Diagnostics is a private, profit-driven software company who provides technology solutions, technical
and integration services and support to pathology laboratories. Gestalt has developed PathFlow, an
enterprise software platform specifically designed to bring the benefits of digital workflow to
pathologists and pathology laboratories. Gestalt has built upon their team's deep experience in
developing and deploying pathology laboratory applications, Laboratory Information Systems, and a
radiology workflow solution that is used for 15 million reads per year. Gestalt's products are
engineered specifically for the unique needs and workflow of pathologists. The PathFlow platform
includes integrated Image Analysis and Artificial Intelligence solutions and algorithms that provide
cancer scoring and image enhancement support for the pathologist.
About BioReference
BioReference Laboratories, Inc., is one of the largest full service specialty laboratories in the United States that
gives healthcare providers and patients the information to make confident healthcare decisions. With a focus
on genetics, oncology, urology and women’s health, BioReference offers comprehensive test solutions and
unparalleled expertise based on a 40 year legacy of proven science. The company is in-network with the
largest health plans in the United States, serves approximately 19 million patients annually, operates a network
of 11 laboratory locations, and is backed by a medical staff of more than 300 M.D., D.O., Ph.D., genetic
counselors and other professional clinical and scientific personnel. With a national footprint and niche market
experience, BioReference provides credible and innovative solutions that meet the needs of employers,
governmental agencies, educational systems, hospitals and health systems, correctional institutions, sports
leagues, travel and leisure industries, and retail markets. BioReference provides industry-leading custom
solutions for COVID-19, including point-of-care testing and large-scale screening programs.
Spokane, Washington, July 9, 2025 – Gestalt, a leading provider of AI-powered digital pathology solutions, showcased its AI-powered pathology platform, PathFlow, at the Spring 2025 DICOM WG-26 Interoperability Connectathon, confirming its readiness for real-world clinical integration and multi-vendor environments. The Connectathon was co-sponsored by the Digital Pathology Association (DPA) and the European Society of Digital and Integrative Pathology (ESDIP). The event, hosted virtually from January to June and featured at the European Congress on Digital Pathology in Barcelona, brought together over 30 organizations to validate end-to-end workflows, in varying categories, using DICOM standards. The categories included image acquisition, storage, viewing, and AI-driven annotations. Gestalt’s platform stood out as a leader in interoperability, particularly as an Image Display (Viewer). Gestalt’s Viewer successfully displayed images from 8 of 9 different WSI Scanners, demonstrating seamless compatibility with multiple diverse systems such as 3DHISTECH, Grundium, Leica, Hamamatsu and Pramana. This robust performance ensures pathologists can access high-quality whole slide images effortlessly, regardless of the source, streamlining diagnostic workflows. Additionally, PathFlow excelled in displaying annotations from five AI Evidence Creators, including industry leaders like Visiopharm, Hologic, TechCyte and identify.bio, further demonstrating its ability to present structured data for precise diagnostic insights. As an Evidence Creator itself, (AI Annotations), Gestalt showcased its advanced AI capabilities, by analyzing and annotating images from eight scanners. These annotations were successfully transmitted to five different image management archives using standard DICOM Web protocols, highlighting Gestalt’s ability to deliver accurate, standards-compliant AI-driven outputs. This functionality empowers pathologists to integrate AI seamlessly into routine clinical operations, improving efficiency and diagnostic accuracy. “Gestalt’s performance at the Connectathon reflects our dedication to building interoperable, scalable solutions that empower pathologists globally,” said Brian Napora, VP of Innovation, Gestalt Diagnostics. “By investing in open standards, we’re helping lead digital pathology toward a more integrated and intelligent future.” The Connectathon’s rigorous testing environment validated Gestalt’s ability to handle real-world challenges, such as legacy image integration and complex multi-vendor workflows without requiring custom workarounds. Gestalt’s commitment to DICOM standards positions PathFlow as a cornerstone for vendor-neutral, future-ready pathology solutions. About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn
July 2025 Digipath Dispatch – Industry news, digital pathology insights, product updates, and events from Gestalt Diagnostics.
Gestalt’s PathFlow and PathCloud unify pathology workflows, enabling seamless, multi-vendor integration for faster, accurate diagnoses.
Discover why digital pathology is gaining momentum and how it’s shaping diagnostics, improving workflows, and addressing workforce challenges in healthcare.
Discover how Lisa-Jean Clifford is helping shape the future of AI in pathology through a new framework designed for safe, scalable clinical integration.
Spokane, Washington, June 17, 2025 – Gestalt, a leading provider of AI-powered digital pathology solutions, today announced the addition of Dr. Renuka Kulkarni, MD, as Chief Medical Officer (CMO). A physician scientist with over 20 years of experience in surgical and digital pathology, Dr. Kulkarni will join the team in guiding Gestalt’s product direction and clinical usability. Dr. Kulkarni brings a rare blend of diagnostic precision and scientific innovation to the organization. Her expertise in breast pathology, immunomarkers, machine learning, and image analysis strengthens Gestalt’s mission to revolutionize diagnostic workflows and clinical decision-making through technology. “Renuka’s addition signals our deepening investment in the future of pathology,” said Lisa-Jean Clifford, President of Gestalt Diagnostics. “Her leadership and experience at the intersection of clinical insight, AI, and enterprise lab operations will ensure our solutions continue to serve both pathologists and the patients they care for.” Before joining Gestalt, Dr. Kulkarni played a pivotal role in developing one of the earliest digital pathology programs at a leading full-service reference laboratory. Her extensive hands-on experience with Gestalt’s solutions, as a customer and direct user for four years, along with image analysis platforms, and combined with her understanding of real-world lab operations, positions her to help bridge the clinical and commercial realms—ensuring the scalability and impact of Gestalt’s solutions. As CMO, Dr. Kulkarni will help shape the development of next-generation diagnostic tools, supporting Gestalt’s mission to enhance diagnostic accuracy, efficiency, and interoperability across health systems worldwide. “I’m honored to join Gestalt at such a transformative moment in digital pathology,” said Dr. Kulkarni. “Together, we have the opportunity to shape solutions that truly serve pathologists and ultimately improve outcomes for patients everywhere.” About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn
Date : Wednesday, May 21, 2025 Time : 1:45 PM Location : Auditorium 1, Marriott Eagle Crest Resort (Ann Arbor, Michigan) Session Title : The Long-Term Advantages of Digital Pathology are Only Realized Through True Interoperability We’re proud to announce that Lisa-Jean Clifford , COO & Chief Strategy Officer at Gestalt Diagnostics, and Sumie Edwards (ARUP) will take the stage at the 2025 Pathology Informatics Summit to share key insights into the critical role of interoperability in digital pathology. In this featured session, Lisa-Jean will explore: Why interoperability is the linchpin for scalable, future-ready digital pathology programs How health systems can unlock long-term value and efficiency through seamless integration Real-world considerations for IT infrastructure, workflow design, and cross-platform compatibility Her session will offer a strategic lens into how institutions can achieve meaningful digital transformation, not just implement new tools. About the PI Summit : The Pathology Informatics Summit is a premier annual event for professionals at the forefront of digital pathology, laboratory medicine, AI, and healthcare data innovation. It brings together leading physicians, researchers, and informaticists to discuss the rapidly evolving field. Mark your calendar for May 21 at 1:45 PM to hear Lisa-Jean share her vision for a more connected and impactful future in pathology.
Date : Thursday, May 22, 2025 Time : 9:00 AM – 12:00 PM Location : Auditorium 1, Marriott Eagle Crest Resort (Ann Arbor, Michigan) Panel Title : API Focus Session: Expert Panel on LDT Regulation Overhaul and Data Challenges in Pathology Informatics Join Lisa-Jean Clifford , COO & Chief Strategy Officer at Gestalt Diagnostics, for an important panel discussion at the 2025 Pathology Informatics Summit alongside top voices in the field of pathology informatics. This focus session will dive into: The impact of the FDA’s Final Rule on Laboratory Developed Tests (LDTs) Data governance, standardization, and access challenges for AI in pathology The urgent need for broadly sourced datasets to support the next generation of clinical AI models Panel Moderator : Ulysses Balis, MD Expert Panelists : Victor Brodsky, MD – Washington University School of Medicine, St. Louis Lisa-Jean Clifford – Gestalt Diagnostics Bruce Friedman, MD Ronald Jackups, MD, PhD – Washington University School of Medicine, St. Louis Amrom Obstfeld, MD, PhD – Children’s Hospital of Philadelphia Michelle Stoffel, MD, PhD – University of Minnesota J. Mark Tuthill, MD – Henry Ford Health System This dynamic session includes two panel discussions followed by open Q&A: The FDA’s Final Rule on LDTs The Growing Crisis of Limited AI Training Data in Pathology Why it matters : With regulatory landscapes shifting and AI innovation surging, this session offers a rare chance to hear from experts shaping the future of diagnostics, data ethics, and clinical technology adoption. Don’t miss this opportunity to learn from Lisa-Jean and fellow leaders who are building the next chapter of pathology informatics.
Spokane, Washington, April 28, 2025 – Gestalt, a leading innovator in AI-powered digital pathology solutions, announced the completion of a $7.5 million Series A financing. The round was led by Cowles Ventures, TVF Funds, Inland Imaging Investments, KickStart Funds, and prominent angel investors from the Pacific Northwest. Gestalt’s PathFlow® platform is used by leading healthcare, academic medical centers, and research organizations. Customers implement PathFlow as their preferred solution because it integrates seamlessly into their existing laboratory information systems, enabling faster, more accurate diagnoses and improving access to expert consultation, education, and research—regardless of location. "PathFlow is transforming pathology by leveraging robust digital workflows and AI algorithms to support scoring of key biomarkers. This enables organizations to accurately match patients to known therapies and generate rich datasets for research and new drug development," said Dan Roark, CEO, Gestalt. "Our technology is designed to improve patient outcomes by enabling faster, more accurate diagnoses and broadening access to clinical expertise." This new funding will facilitate broader market adoption and increased profitability. The capital will be used to expand the company’s customer base, enhance AI capabilities, and pursue FDA clearance. This comes at a critical moment, with rising cancer rates and a declining number of practicing pathologists intensifying the need for scalable, digital-first diagnostic solutions. “We are incredibly grateful for the continued support from our investors,” Roark added. “This funding allows us to expand on the solid foundation we’ve built. We’ve already streamlined how pathologists navigate fragmented systems by creating PathFlow, a unified platform for viewing pathology cases digitally and collaborating with leading experts in real-time without the need to ship specimens. Now, we’ll accelerate innovation and scale our reach to meet the growing demands of modern pathology.” Gestalt is at the forefront of a critical shift in diagnostic medicine, helping transform pathology from a manual, microscope-based process to a scalable digital solution leveraging artificial intelligence tools — like the digital transitions already seen in radiology and cardiology. The company’s platform not only improves diagnostic speed and precision which is critical for cancer patients who can wait for days to weeks or more for a diagnosis, but also unlocks AI-powered insights that enable: Biomarker scoring to support the optimization of patient-therapy matching, Image and data analysis for disease progression studies, And the interoperability that enables pathologists access to valuable aides and insights that streamline their workflows, highlight areas of positivity and reduce missed diagnoses. With this Series A funding, Gestalt remains committed to expanding its impact through the deployment of its’ PathFlow software in healthcare, making high-quality, scalable pathology solutions more accessible to clinicians and researchers worldwide. About Gestalt Gestalt Diagnostics is a Spokane-based company dedicated to revolutionizing pathology through digital solutions. Founded in 2017, Gestalt provides advanced technology, proven digital expertise, and artificial intelligence to enable pathologists to diagnose diseases faster and more efficiently. The company's PathFlow platform is at the forefront of digital pathology innovation, offering significant improvements in diagnostic accuracy and workflow efficiency. To learn more, visit www.gestaltdiagnostics.com and follow @Gestalt on LinkedIn
March 21, 2025 – Mumbai, India and Spokane, Washington – AIRA Matrix, a leading innovator in AI-driven QC solutions, and Gestalt, an industry leader in IMS and digital pathology, have formed a strategic partnership to bring AIRA Matrix’s advanced AI solution, AIRAQC, to Gestalt's PathFlow. This collaboration marks a significant step toward enhancing diagnostic precision and efficiency in laboratories worldwide. AIRAQC, powered by cutting-edge artificial intelligence, streamlines quality control processes, enabling faster and more accurate analysis in pathology workflows. By integrating AIRAQC with Gestalt's workflows, pathologists will gain access to a seamless, AI-enhanced experience designed to optimize diagnostic decision-making. "We're thrilled to partner with Gestalt to expand the reach of AIRAQC and deliver transformative AI capabilities to pathology labs," said Marco Comianos, Head of Commercial Operations - US., AIRA Matrix. "This collaboration is a testament to our shared commitment to advancing pathology through innovation." “The partnership between AIRA Matrix and Gestalt represents a continued effort to drive progress in pathology by leveraging technology to meet evolving healthcare needs. Together, our companies aim to empower laboratories with state-of-the-art tools that improve diagnostic accuracy, quality and meaningful metrics from the start of the diagnostic process” says Lisa-Jean Clifford, Gestalt COO & Chief Strategy Officer. About AIRA Matrix: Delivers artificial intelligence solutions for healthcare and life sciences applications. Our innovative products and services drive efficiency, enhance diagnostic accuracy, and provide data-driven insights from digitally scanned images. Our comprehensive AI-driven suite for drug discovery and development, streamlines pre-analytical quality control, facilitates tissue triage, and optimizes safety and efficacy assessments, accelerating breakthrough discoveries. Our healthcare portfolio offers diagnostic, prognostic, and predictive tools that facilitate risk stratification and enable personalized therapy planning, thus improving treatment outcomes., visit www.airamatrix.com. About Gestalt Diagnostics: Gestalt transforms pathology through an intelligent, configurable, vendor-neutral, and AI-driven digital workflow that provides true interoperability enabling pathologists to diagnose* diseases faster and more efficiently. Our PathFlow® solution consists of professional, education, and research modules for ease of mixing and matching the digital needs of your facility in a single solution, freeing pathologists from tedious, repetitive, and manual tasks allowing them to focus on their expertise, providing invaluable experience where it matters most. *Following the LDT process in the US. It is under CE-IVD marking for use in Europe.
